Table 2.
The ongoing clinical trials of nanocarriers for the treatment of glioblastoma multiforme [217].
| NCT Number | Title | Conditions | Outcome Measures | Phases | Last Update Posted |
|---|---|---|---|---|---|
| NCT05768919 | Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas | Glioblastoma | The number of observed Dose Limiting Toxicity (DLTs) The incidence of Adverse Events The proportion of patients at each dose level who receive at least 80% of the planned infusions of LC, 80% of RT, and 60% of TMZ during the first 10 weeks of treatment. Overall Survival (OS) Progression-free survival (PFS) |
Phase 1 Phase 2 |
15 March 2023 |
| NCT04573140 | A Study of RNA-lipid Particle (RNA-LP) Vaccines for Newly Diagnosed Pediatric High-Grade Gliomas (pHGG) and Adult Glioblastoma (GBM) | Adult Glioblastoma | Manufacturing feasibility Safety of RNA-LP vaccine Determination of Maximum Tolerated Dose |
Phase 1 | 21 February 2023 |
| NCT01906385 | Maximum Tolerated Dose, Safety, and Efficacy of Rhenium Nanoliposomes in Recurrent Glioma (ReSPECT) | Glioma | Phase 1: Maximum Tolerated Dose Phase 2: Overall Survival Phase 1: Dose Distribution Phase 1: Response rate Phase 1: Survival Phase 1: Safety of single dose of treatment Phase 2: Safety and tolerability of 186RNL Phase 2: Objective response rate (ORR) Phase 2: Progression-free survival at 6 months (PFS-6) Phase 2: Progression-free survival (PFS) from the initiation of study to first documented progression Phase 2: Quality of Life |
Phase 1 Phase 2 |
12 December 2022 |
| NCT05460507 | Safety & Efficacy/Tolerability of Rhenium-186 NanoLiposomes (186RNL) for Patients Who Received a Prior 186RNL Treatment | Glioma | Assessment of safety and tolerability of a second dose of 186RNL by CED as part of standard of care > 30 days following first dose. Overall Survival Dose Distribution Overall Response Rate Progression-free survival |
Phase 1 | 23 December 2022 |
| NCT04881032 | AGuIX Nanoparticles With Radiotherapy Plus Concomitant Temozolomide in the Treatment of Newly Diagnosed Glioblastoma | Glioblastoma | The recommended dose (phase I) of AGuIX in combination with TMZ and radiotherapy during the radio-chemotherapy period 6-month Progression-Free Survival (PFS) rate (phase II) Pharmacokinetic Cmax of AGuIX Pharmacokinetic Tmax of AGuIX Pharmacokinetic AUC of AGuIX Pharmacokinetic t1/2 of AGuIX distribution of AGuIX Overall Survival Progression-Free Survival (PFS) Toxicity (CTCAE criteria) |
Phase 1 Phase 2 |
8 March 2023 |